Efficacy of alogliptin/metformin combination tablets(INISYNC combination tablets) in type 2 diabetic patients.

Not Applicable

Recruiting

• Conditions: Type 2 diabetes

• Registration Number: JPRN-UMIN000034599
• Lead Sponsor: Minami Osaka hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-22
• Study Completion: 2019-02-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with a history of lactic acidosis. 2)Patients with moderate or severe renal dysfunction(eGFR<45mL/min/1.73m2). 3)Patients with severe liver dysfunction such as active hepatitis and liver cirrhosis. 4)Patients with heart failure and acute myocardial infarction, pulmonary embolism such as advanced disability cardiovascular system and lung function. 5)Patients with excessive alcohol intake. 6)Patients with severe infections, before and after surgery, serious trauma. 7)Patient with malignant disease. 8)Pregnant women or patients who may be pregnant.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The changes in HbA1c from the start of administration up to 6 months

Secondary Outcome Measures

Name	Time	Method
1)Body weight 2)Compliance 3)Comparison with pretreatment drugs